Nabriva Therapeutics PLC - ADR Stock Nasdaq
Equities
US62957M1045
Biotechnology & Medical Research
Financials (USD)
Sales 2021 | 28.9M | Sales 2022 | 36.94M | Capitalization | 5.79M |
---|---|---|---|---|---|
Net income 2021 | -49M | Net income 2022 | -57M | EV / Sales 2021 | -0.2 x |
Net cash position 2021 | 39.64M | Net cash position 2022 | 7.19M | EV / Sales 2022 | -0.04 x |
P/E ratio 2021 |
-0.53
x | P/E ratio 2022 |
-0.09
x | Employees | - |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 99.05% |
Managers | Title | Age | Since |
---|---|---|---|
H. Hogan
CEO | Chief Executive Officer | 61 | 23-07-06 |
Dave Maggio
DFI | Director of Finance/CFO | 64 | 23-06-29 |
Steven Gelone
BRD | Director/Board Member | 56 | 17-06-22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Burgess
CHM | Chairman | 62 | 17-06-22 |
Director/Board Member | 69 | 18-07-23 | |
Stephen Webster
BRD | Director/Board Member | 63 | 16-07-31 |
1st Jan change | Capi. | |
---|---|---|
-1.51% | 104B | |
+3.22% | 97.42B | |
+0.84% | 22.2B | |
-16.53% | 21.23B | |
-8.70% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |